

**MINUTES OF TECHNICAL EVALUATION COMMITTEE MEETING OF RE-TENDER
BMSIC/DRUGS/19-03 (RATE CONTRACT AND SUPPLY OF DRUGS FOR DIFFERENT
HEALTHCARE FACILITIES OF STATE OF BIHAR).**

Date: 28th May 2019

Venue: BMSICL Conference Hall.

The **Technical Evaluation Committee Meeting of Tender No. BMSIC/DRUGS/19-03** was held on 28th May 2019 under the Chairmanship of Dr. R. D. Ranjan, Director in Chief, Department of Health, GoB. The other committee members present in the meeting were:

1. Sh. Anil Kumar, Joint Secretary, Department of Health, GoB.
2. Sh. Khalid Arshad, AO, State Health Society.
3. Sh. Rajani Kant, CGM (Supply Chain), BMSICL.
4. Dr. N. K. Mishra, Additional Director, Department of Health, GoB.
5. Sh. Sunil Kumar Singh, GM (Logistics), BMSICL.
6. Dr. Biswaprakash Pradhan, DGM (Drugs), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/19-03.
2. Tender floated date- 28/01/2019
3. Last date of submission of Online bids- 03/04/2019
4. Tender Opening date- 08/04/2019.

3. Tender has been floated for 9 (Nine) drugs. It was found in online opening that the following 2 (Two) bidders had participated in the tender:


1. Baxalta Bioscience India Pvt. Ltd.
2. Hemarus Therapeutics Ltd.

4. The summary of bid received status were as follows:

1. No Bid received for 8 Drugs.
2. Multiple Bids received for 1 Drug.

5. It was unanimously decided in Tender Opening Committee meeting dated 08.04.19 to proceed further for preliminary technical evaluation of both the received bids for NIT S. No. 1 (Human Coagulation Factor IX) for which multiple bids were received, by the team of Drug Inspectors deputed at BMSICL and re-tender for the remaining 8 Drugs (NIT S. No. 2,3,4,5,6,7,8 & 9) due to no bid condition.

6. The Preliminary Evaluation of technical bids of the above mentioned bidding firms were done by the team of Drug Inspectors deputed at BMSICL. Evaluation sheets were published on the website of BMSICL and Claims/objections/clarification were invited vide notice no. 602 dated 09.05.2019.

Biswaprakash
Sh
Ranjan
MS
Sh


7. After comparison of the clarification received from the bidders in the light of that notice and close examination of the documents submitted by the bidders, the drug wise technical evaluation findings are recorded as follows:

S. N	Name of the Drugs with Specification	Participating Firms	Remarks of the TEC
1	Human Coagulation Factor IX (Dried powder for Injection 600IU)	Baxalta Bioscience India Pvt. Ltd	Technically Qualified
		Hemarus Therapeutics Ltd.	Technically Qualified

8. M/s Baxalta Bioscience India Pvt. Ltd is one importer firm and M/s Hemarus Therapeutics Ltd. is one manufacturer. Hence it was unanimously recommended to carryout the inspection of the manufacturing unit of M/s Hemarus Therapeutics Ltd.

9. The meeting was thus concluded with a vote of thanks.

B Pradhan
28/05/2019
(Dr. Biswaprakash Pradhan)
DGM (Drugs), BMSICL, Patna

S.K.
28/05/2019
(Sunil Kumar Singh)
GM (logistics), BMSICL, Patna

N.K. Mishra
28/5/19
(Dr. N. K. Mishra)
Additional Director, Health
Dept., Govt. of Bihar

Anil Kumar
28.5.2019
(Anil Kumar)
Joint Secretary, Department
Health, GoB

Khalid Arshad
28/5/19
(Khalid Arshad)
Administrative Officer, SHSB.

Rajani Kant
28/5/19
(Rajani Kant)
CGM (Supply Chain), BMSICL,
Patna.

R.D. Ranjan
28/5/19
(Dr. R.D. Ranjan)
Director in Chief, Health Dept.
Govt. of Bihar.

